Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Analysis of the role of baseline PET/CT in a prospective study of unselected patients: The UK MCL biobank

View Full Paper
Ask AI
Bookmark
Share

Authors

GNGeorgina NaylorSMSarah MantAOA. I. Omar

Discussion

Loading...

Member takes

Overview

Prospective analysis shows baseline PET imaging predicts progression free survival in mantle cell lymphoma, highlighting treatment implications.

Key Points

  • Higher metabolic tumour volume predicts shorter progression free survival in mantle cell lymphoma, influencing treatment decisions.
  • Analysis of baseline PET scans of 150 patients reveals significant outcomes linked with metabolic tumour volume and treatment pathways.
  • Prospective observational study across multiple sites in the UK utilized comprehensive imaging and clinical data on untreated mantle cell lymphoma patients.
  • Findings underscore the need for tailored treatment strategies for mantle cell lymphoma and the potential role of PET imaging in management.

Cite This Study

Naylor et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e000https://doi.org/10.1182/blood-2025-5376
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Performance of radiomics features in patients with peripheral T-cell lymphoma: Data from international prospective T-cell project 2.02025
  2. 2Prognostic impact of Mantle Cell Lymphoma frontline induction response assessments in the ECOG-ACRIN E1411 study of bendamustine-rituximab +/- bortezomib and maintenance with rituximab +/- lenalidomide2025
  3. 3PET imaging biomarkers predict survival in peripheral T-cell lymphoma: A systematic review and meta-analysis.2025
  4. 4Utility of 18F-FDG PET/CT for response assessment in marginal zone lymphomas: Preliminary results of the IELSG44 international study2025 · 2 citations
  5. 5Validated PET-CT metabolic tumor volume threshold identifies high-risk relapsed/refractory LBCL and predicts 12-month toxicity-free progression-free survival Post–CAR-T therapy2025